Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

ovarian adenocarcinoma - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

ovarian adenocarcinoma

MONDO:0002752

Also known as:adenocarcinoma of ovaryadenocarcinoma of the ovaryovary adenocarcinoma

Find Clinical TrialsTrials

Overview

An adenocarcinoma that arises from the ovary. It is the most common type of ovarian carcinoma. It includes the serous adenocarcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma, and endometrioid adenocarcinoma.

Treatments2 FDA approved

Clinical Trials15 registered · 2 recruiting

Diagnosis

Biomarker and diagnostic research for ovarian adenocarcinoma has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for ovarian adenocarcinoma, including CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE, approved 2020) and THIOTEPA (TEPADINA, approved 2017).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

15 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 1 PHASE3, 6 PHASE2, 5 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05601700](https://clinicaltrials.gov/study/NCT05601700)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 1:12 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:213504

GARD

Genetic and Rare Diseases Info Center

GARD:20466

Questions for Your Care Team

→What are the benefits and potential side effects of CYCLOPHOSPHAMIDE for managing ovarian adenocarcinoma?
→Are any of the 15 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	40	40%
Laboratory research	32	32%
New treatment approaches	10	10%
Testing and diagnosis research	6	6%
Research summaries	6	6%
Disease patterns and progression	4	4%
Clinical study results	2	2%
Other research	1	1%

ovarian adenocarcinoma

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications